Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
- MACD is crossing MACD signal line at 0.7. MACD crossing signal line is bullish signal.
|Earning Growth (QoQ)||63%|
|Revenue Growth (QoQ)|
|Held by Institutions %||87%|
|1 Day Vol Adjusted Return||-0.2|
|1 Month Vol Adjusted Return||-3.3|
|3 Month Vol Adjusted Return||-1.5|
|6 Month Vol Adjusted Return||-3.2|
|20 Days SMA Price ZScore||0.5|
|50 Days SMA Price ZScore||-0.5|
|12 -26 Days PPO||-1.0|
|1 Month Average Short Volume Ratio||40.5|
|1 Day Volume Change ZScore||-1.8|
|1 Month Daily Vol||1.2|
BDX vs. MMSI: Which Stock Is the Better Value Option?
In this article, we discuss the 10 best healthcare stocks to buy. You can skip our detailed analysis of the healthcare sector and go directly to read the Retirement Stock Portfolio: 5 Healthcare Stocks To Consider. In the initial months of the pandemic, the S&P 500 Healthcare index outperformed the S&P 500 by 6.85 percentage […]
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a new strategy to advance environmental, social and governance (ESG) initiatives, as well as a suite of goals for 2030 and beyond that focus on enhancing stewardship of the company, the planet, community and human health.
BD's (BDX) latest manufacturing line is expected to not only boost supply capacity but also provide priority access to needles and syringes to the U.S. government.
BD's (BDX) Rotarex Atherectomy System receives expanded 510 (k) clearance from the FDA that can help in the treatment of in-stent restenosis in the United States.
Becton Dickinson and Co said on Thursday it had added manufacturing lines for safety injection devices at its facility in Nebraska, boosting supply of syringes as the United States heads into the flu vaccination season while administering COVID-19 jabs. The $70 million expansion was supported by a $42 million investment by the Biomedical Advanced Research and Development Authority in July last year, as the U.S. government sought to secure priority access to "hundreds of millions of injection de...
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has strengthened the U.S. government's access to safety injection devices through increased manufacturing capacity and domestic supply. The new syringe and needle manufacturing lines, which were completed on an accelerated timeline, represent the public-private partnership between BD and Department of Health and Human Services' (HHS) Assistant Secretary for Preparedness and Response (A
It is hard to get excited after looking at Becton Dickinson's (NYSE:BDX) recent performance, when its stock has...